CTOs on the Move

paramedics plus

www.paramedicsplus.com

 
paramedics plus is a Tyler, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Community Medical Services

Community Medical Services is a CARF–accredited addiction treatment program providing services in the form of outpatient medication-assisted treatment and private one–on–one and group counseling, Intensive Out-Patient therapy (IOP) and Moral Reconation Therapy (MRT) to those seeking help with their substance use disorders. We have a total of 14 clinics throughout the United States. We have seven Arizona locations which cater to Phoenix, Glendale, Mesa, Scottsdale, and Tempe; a clinic in East Tucson, Northwest Tucson, Safford and Casa Grande; four clinics in Montana located in Missoula, Kalispell, Billings and Belgrade, which cater to clients in Bozeman and Helena; a clinic in Wasilla, Alaska catering to the Mat-Su Valley and Anchorage, and two clinics in North Dakota, one located in Minot, catering to clients in Williston and Bismarck and a clinic in Fargo, catering to clients from Fargo/Moorhead, West Fargo, Grand Forks, and Minnesota.

PREtest Consult

PREtest Consult is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MxSecure

Recognized by Entrepreneur Magazine as one of ten healthcare companies to watch, MxSecure provides productivity enhancing solutions to thousands of healthcare providers in more than 600 medical facilities nationwide.

Connolly Strategies and Initiatives

Connolly Strategies and Initiatives is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.